A prospective pilot study of a novel alemtuzumab target concentration intervention strategy-Reference-Cited by-同舟云学术

A prospective pilot study of a novel alemtuzumab target concentration intervention strategy

Published:2021-09-21 Issue:12 Volume:56 Page:3029-3031
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Arnold Danielle E.,Emoto Chie,Fukuda Tsuyoshi,Dong Min,Vinks Alexander A.,Lane Adam,McIntosh Kelly,Neumeier Lisa,Lankester Arjan C.^ORCID,Achini Federica,Teusink-Cross Ashley,Chandra Sharat,Jordan Michael B.,Nelson Adam S.,Myers Kasiani C.^ORCID,Davies Stella M.,Mehta Parinda A.,Marsh Rebecca A.^ORCID

Funder

Cincinnati Children’s Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01460-1.pdf

Reference9 articles.

1. Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P. et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 2010;116:3080–8. https://doi.org/10.1182/blood-2010-05-286856.

2. Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M. et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transpl. 2013;19:1625–31. https://doi.org/10.1016/j.bbmt.2013.09.001.

3. Gartner F, Hieke S, Finke J, Bertz H. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery. Cytotherapy. 2013;15:1237–44. https://doi.org/10.1016/j.jcyt.2013.05.016.